4.7 Article

EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

Journal

EUROPEAN JOURNAL OF CANCER
Volume 48, Issue 5, Pages 599-641

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2011.12.021

Keywords

-

Categories

Funding

  1. Bayer Pharmaceutical
  2. BMS
  3. Biocompatibles
  4. Novartis
  5. Abbot
  6. Imclone
  7. Jennerex
  8. Bayer
  9. Terumo
  10. Roche
  11. Gilead
  12. Idenix
  13. Vertex
  14. MSD
  15. Anadys
  16. Globe Immune
  17. Pharmasset
  18. Salix
  19. Merck
  20. Pfizer
  21. Lilly
  22. Bayer Health Care
  23. AIRC (Italian Association for Cancer Research)
  24. European Community
  25. Bayer SPA
  26. MDS Nordion
  27. Astellas
  28. BMS Bayer Schering Pharma AG
  29. GSK
  30. Kowa
  31. Sumitomo
  32. Arqule
  33. Gilead Science
  34. Tibotec
  35. Sanofi-Aventis

Ask authors/readers for more resources

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available